Nurix + Roche; Global BTK Degrader Collaboration
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
All categories
AbbVie – EHA 2026 Hematology Portfolio Update
AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a…
Lilly + Ascidian – $1.9B RNA Exon Editing Deal
Eli Lilly signed a collaboration with Ascidian worth up to $1.9B to develop in vivo RNA exon-editing therapies for inherited kidney diseases, validating RNA exon editing as a major emerging genetic medicine modality.
Karyopharm – SENTRY Phase 3 Full Data in Frontline Myelofibrosis
Karyopharm delivered one of the most important myelofibrosis datasets of 2026. In the Phase 3 SENTRY study, selinexor plus ruxolitinib nearly doubled spleen response rates versus ruxolitinib alone (49.8% vs 28.0%) and generated an…
Kelonia Therapeutics – In Vivo CAR-T Clinical Update
Kelonia Therapeutics presented updated ASCO 2026 data supporting continued advancement of its in vivo CAR-T platform, which engineers CAR-T cells directly inside patients using targeted lentiviral delivery technology.
TUNE-401 Epigenetic Silencing Clinical PoC
Tune Therapeutics presented the first clinical proof-of-concept data for CRISPR-based epigenetic silencing in humans, demonstrating deep, dose-dependent and durable reductions in HBV biomarkers with TUNE-401 in chronic hepatitis B patients.
Karyopharm – SENTRY Phase 3 Myelofibrosis Readout Watch
Karyopharm announced an investor conference call following the June 2, 2026 ASCO oral presentation of full Phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
YolTech – In Vivo CRISPR/Base Editing Platform Financing
YolTech Therapeutics raised $70M in a Series C financing to expand what is currently one of China’s most advanced in vivo CRISPR and base-editing platforms, with programs spanning sickle cell disease, beta-thalassemia, ATTR, familial…
OPTI-AML Venetoclax Optimization
Blood Cancer United announced more than 50 ASCO and EHA 2026 abstracts, highlighted by an oral EHA presentation from the randomized Phase 2 OPTI-AML substudy evaluating reduced-duration venetoclax dosing with azacitidine in newly diagnosed…
Waypoint Bio – China IIT CAR-T Strategy
Waypoint Bio emerged from stealth with a $20M Series A financing to advance multiple CAR-T investigator-initiated trials in China while developing an AI-enabled spatial pooled screening platform for next-generation target discovery.
